Ruijin Hospital: Lymphoma, B-Cell trials

The registry lists 38 Lymphoma, B-Cell studies with Ruijin Hospital as lead sponsor. 25 are open to participants now and 0 have results posted.

Early Phase 1 1Phase 1 3Phase 2 16Phase 3 4Phase 4 2No phase 13(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Evaluation of GI001 for Relapsed or Refractory B-cell Non-Hodgkin LymphomaNot yet recruitingNCT07584850Early Phase 1
• Clinical Study of XP-006 mRNA Vaccine for R/R B-NHLNot yet recruitingNCT07334574Phase 1
• A Study of mRNA Encoding CD19/CD3 T Cell Engager (ABO2203) in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (B-NHL)RecruitingNCT07072169Phase 1
• Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel Injection as First-Line Therapy of High-Risk Large B-Cell LymphomaNot yet recruitingNCT06935136Not applicable
• PET Imaging Targeting Granzyme B Predicts Immunotherapy Efficacy in Diffuse Large B-cell LymphomaRecruitingNCT06755775
• Dynamic CtDNA-guided Targeted Therapy in DLBCLNot yet recruitingNCT06748521Phase 2
• Zanubrutinib-based Maintenance Therapy of Newly Diagnosed DLBCL With Initial RemissionNot yet recruitingNCT06669143Phase 2
• The Effectiveness and Safety of Glofitamab in Real-World Clinical Practice Among Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Prospective, Observational, Multicenter StudyNot yet recruitingNCT06656234
• Mechanism Investigation of R-CHOP Regimen or Tucidinostat Plus R-CHOP (CR-CHOP) Regimen in the Treatment of BCL2/MYC Protein Double Expressor LymphomaNot yet recruitingNCT06652152
• Selinexor Combined With BEAM for ASCT in R/R DLBCL With MYC PositiveNot yet recruitingNCT06652139Phase 2
• ARTA-based Chemo-free Bridging/Maintenance Therapy in CAR-T Treatment for High-Risk R/R B-NHL Ineligible for HDCT and ASCTNot yet recruitingNCT06646666Phase 2
• A Real-World Study on Extranodal LymphomaNot yet recruitingNCT06573099
• CAR T-cell Therapy in Combination With Glofitamab for Relapsed/Refractory Large B-Cell Lymphoma With High-Risk Prognostic FactorsNot yet recruitingNCT06567366Phase 2
• The Efficacy and Safety of Pola-ZR2 Versus ZR2 in the Treatment of Old Patients With de Novo Diffuse Large B-cell LymphomaRecruitingNCT06522555Phase 3
• Efficacy of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCLNot yet recruitingNCT06441097Phase 2
• CAR-T Following ASCT for Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (R/R B-NHL) With High-Risk Prognostic FactorsRecruitingNCT06365671Phase 2
• Selinexor Combined With R-GDP Regimen for TP53-altered R/R DLBCLNot yet recruitingNCT06062641Phase 2
• Real-World Study of DLBCL With Different Genetic SubtypesRecruitingNCT06026488
• A Retrospective Study on Extranodal Lymphoma or Lymphoma of Rare Pathological TypesNot yet recruitingNCT05907447
• Efficacy and Safety of Venetoclax Combined With BEAM Pretreatment in Autologous Transplantation for DLBCLNot yet recruitingNCT05863845Not applicable
• Secondary Infusion of Relma-cel Injection for Relapsed or Refractory B-cell LymphomaRecruitingNCT05806580Phase 4
• Genotype-guided Treatment in DLBCLRecruitingNCT05351346Phase 3
• Novel Targeted Drugs Combined With R-ICE Regimen in Relapsed and Refractory Diffuse Large B-cell LymphomaRecruitingNCT05348213Phase 2
• The Efficacy and Safety of ZR2 Versus R-miniCHOP in the Treatment of Unfit or Frail de Novo Diffuse Large B-cell Lymphoma Patients Aged Older Than or Equal to 70 YearsRecruitingNCT05179733Phase 3
• Cell Free DNA in Mature B-cell LymphomaRecruitingNCT04088422
• A Retrospective Study on Extranodal DLBCLCompletedNCT06549361
• Mechanism of Resistance to GNC-038 in Relapsed and Refractory Diffuse Large B-cell LymphomaStatus unknownNCT05189782
• Zanubrutinib Combined With Tislelizumab in the Treatment of r/r PMBCL and EBV+ DLBCLStatus unknownNCT04705129Phase 2
• Zanubrutinib, Lenalidomide and Rituximab (ZR2) in Elderly Treatment-naive Patients With Diffuse Large B-cell Lymphoma (DLBCL)Active, not recruitingNCT04460248Phase 2
• Efficacy and Safety of Lenalidomide With or Without Rituximab and Other Drugs in B-cell Non-Hodgkin's LymphomasStatus unknownNCT04435743
• Study Evaluating the Safety and Efficacy of iR2 in Untreated and Unfit Elderly Patients With DLBCLStatus unknownNCT03949062Phase 2
• Lenalidomide Based Immunotherapy in the Treatment of DLBCLStatus unknownNCT03715296
• Lenalidomide Plus ICE in the Treatment of Refractory and Relapsed DLBCLStatus unknownNCT03367143Phase 2
• Decitabine Plus R-CHOP in Diffuse Large B-cell LymphomaStatus unknownNCT02951728Phase 1/2
• Chidamide Plus R-CHOP in Elderly DLBCLStatus unknownNCT02753647Phase 2
• Reduced Chemotherapy in Low Risk DLBCLStatus unknownNCT02752815Phase 4
• A Study of Bortezomib Plus GDP in the Treatment of Refractory and Relapsed Non-GCB DLBCLStatus unknownNCT02542111Phase 2
• R-CEOP-90/R-CEOP-70 Versus R-CHOP-50 in the Treatment of Diffuse Large B-cell Lymphoma and Follicular Lymphoma Grade 3BStatus unknownNCT01852435Phase 3